Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)
Debora Basile(University of Udine), M. Svrcek(Sorbonne Université), Jaafar Bennouna(Hôpital Foch), Pascal Artru(Université Paris Cité), François Ghiringhelli(Inserm), Laurent Mineur(Institut Sainte Catherine), T. André(Sorbonne Université), Valentin Dérangère(Inserm), Franck Pagès(Inserm), Serge Fratté(Université de technologie de belfort-montbéliard), Jean-François Emile(Université de Versailles Saint-Quentin-en-Yvelines), C. Louvet(Institute Mutualiste Montsouris), Déwi Vernerey(Inserm), Chloé Broudin(Assistance Publique – Hôpitaux de Paris), Alexandre Falcoz(Inserm), Julien Taı̈eb(Hôpital Européen Georges-Pompidou)
Cited by 44
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k